Core Viewpoint - The acquisition of Skyline Therapeutics Limited's assets by Teabo Bio is a strategic move aimed at future technology development rather than short-term profit maximization [1][2] Group 1: Acquisition Details - Teabo Bio's wholly-owned subsidiary, Xiamen Borsai Gene Transcription Technology Co., Ltd., completed the acquisition of certain assets from Skyline Therapeutics Limited on July 29 [1] - The acquisition includes the AAV platform and a pipeline of products under development for conditions such as spinal muscular atrophy (SMA) and retinal diseases [1] - Skyline Therapeutics Limited has research and production bases in Shanghai, Hangzhou, and Boston, and operates five companies under its umbrella [1] Group 2: Strategic Intent - The company aims to transition from a product and technology-centric organization to one that utilizes multiple platforms and tools to address disease issues [2] - The integration of the acquired technology platform is expected to enhance the company's capabilities in the immunology and metabolism fields, providing more treatment options for patients [2]